Fairvoy Private Wealth Boosts Incyte Corporation Holdings

Hedge fund increases stake in biopharmaceutical company by nearly 470%

Mar. 28, 2026 at 8:36am

Got story updates? Submit your updates here. ›

Fairvoy Private Wealth LLC significantly increased its holdings in Incyte Corporation (NASDAQ:INCY), the biopharmaceutical company, by adding 24,865 shares during the fourth quarter. The hedge fund now owns 30,169 shares of Incyte's stock, worth $2.98 million at the end of the reporting period.

Why it matters

This investment by Fairvoy Private Wealth reflects growing institutional investor interest in Incyte, which develops and commercializes novel therapies for cancer, autoimmune disorders, and rare diseases. Incyte's flagship product is the JAK inhibitor Jakafi, approved for treating myelofibrosis and polycythemia vera.

The details

According to a 13F filing with the SEC, Fairvoy Private Wealth lifted its holdings in Incyte by 468.8% during the fourth quarter. The firm now owns 30,169 shares of the biopharmaceutical company's stock, up from just 5,304 shares held at the end of the prior quarter.

  • Fairvoy Private Wealth increased its Incyte holdings during the fourth quarter of 2025.
  • The 13F filing reporting this increase was submitted on March 28, 2026.

The players

Fairvoy Private Wealth LLC

A hedge fund that significantly increased its stake in Incyte Corporation during the fourth quarter.

Incyte Corporation

A biopharmaceutical company focused on developing and commercializing novel therapies for cancer, autoimmune disorders, and rare diseases. Its flagship product is the JAK inhibitor Jakafi.

Got photos? Submit your photos here. ›

The takeaway

This investment by Fairvoy Private Wealth highlights the growing institutional interest in Incyte as the company continues to advance its pipeline of innovative therapies for difficult-to-treat conditions. The significant increase in Fairvoy's stake suggests the hedge fund sees strong potential in Incyte's future performance and prospects.